www.public4you.fora.pl

njlpkhgea

,[link widoczny dla zalogowanych]
Adefovir dipivoxil,[link widoczny dla zalogowanych], and lamivudine therapy compared the efficacy of hepatitis B cirrhosis

T-test. Comparison of count data using x test. Test level 0 【= 0.05,[link widoczny dla zalogowanych], P <0.05 was statistically significant. 2 Results 2.1 The two groups of liver function in patients with normalization of the situation shown in table l. Two groups of patients 6 months of treatment, liver function, albumin addition to the indicators, the lamivudine group than the number of complex common practice adefovir group, but the difference was not statistically significant. With the extension of treatment, two groups of liver function in patients with increases in both the number of complex common practice until the end of treatment, both groups of liver function of patients number of complex common practice, the difference was not significant. Changes in the two groups were 2.2 HBVDNA HBVDNA levels of the two groups were not different before treatment, treatment for 3 months. HBVDNA levels decreased significantly compared with before treatment (P all <0.01), but the difference between the two groups was not significant. 3 months negative rate 比阿德福韦 lamivudine group ester group, but the difference was not statistically significant. With the extension of treatment, each group HBVDNA level decreased, the negative rate also increases. HBVDNA two groups at each time point and the negative rate levels, the difference was not significant, Table 2. 2-3 patients were treated HIV drug resistance mutations compared to 9 months, two patients had no virus mutation resistance occurred at 12 months of lamivudine treatment group YMDD mutation occurred in 1 case. Mutation rate of 5.0%. Adefovir dipivoxil treatment group still no virus mutations. Practical Journal of Medicine Volume 26, 2010 115 Table l l groups of liver function in patients with normalization of situation in cases of two groups of patients Table 3 Changes of serum liver fibrosis x-4-. txg/mL2.4 two groups of liver fibrosis markers results in Table 3. The patients before the serum PC Ⅲ, Ⅳ a C, LN, HA values were higher, no significant difference between the two groups. 3 months treatment serum PCm, Ⅳ a C, LN, HA, compared with before treatment decreased the value is not obvious, at 6 months of serum PC Ⅲ, 1V. C, LN, HA was significantly decreased (compared with before treatment group, P all <0.01), and with the extension of treatment serum Pc Ⅲ, Ⅳ a C, LN, HA value is further reduced, but the two groups of patients each time point, the difference was not significant adverse reactions during treatment of 2.5 was found with the use of adefovir dipivoxil with lamivudine-related renal dysfunction, adefovir dipivoxil treatment group, 1 patient developed a headache , fatigue, abdominal distension, lamivudine group, 1 patient with nausea, loss of appetite, indigestion, diarrhea, but tolerable, no patients discontinued treatment due to adverse events. 3 In addition to discussing the treatment of liver cirrhosis and liver inflammation, symptomatic and supportive, anti-fibrosis treatment, antiviral therapy is the key. Nucleoside analogues are widely recognized as one of effective antiviral drugs. ... Lamivudine treatment efficacy in patients with liver cirrhosis have been positive E2-3. Adefovir Adefovir dipivoxil is a precursor, a single phosphate oxygen of 5 Vidarabine free ring analogs, hydrolysis in vivo antiviral activity of adefovir play. In this study, these two drugs on the liver cirrhosis patients were 12 months of antiviral therapy comparison of observed results show that the liver function indicators (A, AST, Alb, TBil) the recovery of adefovir dipivoxil group compared with the lamivudine group, the difference was not statistically significant. HBVDNA negative in serum, the two groups of patients before treatment HBVDNA levels were significantly lower than that, but between the two groups, no statistically significant difference. The rate of resistance mutations in the virus, the end of treatment, adefovir dipivoxil was no virus mutations. Lamivudine group, 1 case of YMDD mutation, mutation rate of 5.0%. This result is similar to the results reported in the literature [. Two groups of patients before treatment, serum Pc Ⅲ, Ⅳ. c, LN, HA values were higher when the 3 months of treatment serum PCm, IV. C, LN, HA, compared with before treatment decreased the value is not obvious, at 6 months of serum Pc Ⅲ, Ⅳ. C, LN, HA was significantly decreased, and with the extension of treatment serum Pc Ⅲ, Ⅳ. C, LN, HA value is further reduced, but the two groups were compared at each time point. The difference was not statistically significant. Results Table 明阿德福韦 ester and lamivudine resistant hepatitis and liver cirrhosis patients had significant fibrosis. In conclusion, adefovir dipivoxil and lamivudine in terms of clinical efficacy and safety similar to, but the virus mutation rate than lamivudine resistance is low. Is an effective anti-HBV drugs, and one of the ideal, but more time after the application of the efficacy and safety remains to be seen. 4